Nascent Biotech, Inc. (NBIO)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nascent Biotech, Inc. (NBIO) with AI Score 42/100 (Weak). Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing monoclonal antibodies for cancer treatment. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Nascent Biotech, Inc. (NBIO) Healthcare & Pipeline Overview
Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company specializing in monoclonal antibody development for cancer therapies, including Pritumumab for brain and epithelial cancers. The company's MultiPharm platform expands its focus to diabetes, autoimmunity, and transplantation, positioning it within the competitive biotechnology landscape.
Investment Thesis
Nascent Biotech, Inc. presents a high-risk, high-reward investment opportunity typical of clinical-stage biopharmaceutical companies. The primary value driver is the successful development and commercialization of Pritumumab, targeting a significant unmet need in brain and epithelial cancer treatment. Positive clinical trial results for Pritumumab would serve as a major catalyst, potentially leading to significant stock appreciation. The MultiPharm platform offers additional long-term potential, expanding the company's therapeutic scope beyond cancer. However, the company's reliance on OTC markets and limited financial information increase the investment risk. The company's negative P/E ratio of -0.02 reflects its current lack of profitability. Investors should carefully assess the risks associated with clinical-stage biotech companies and the uncertainties of OTC trading.
Based on FMP financials and quantitative analysis
Key Highlights
- Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing monoclonal antibodies for cancer treatment.
- The company's lead drug, Pritumumab, targets brain cancer malignancies and epithelial cancers.
- MultiPharm, a proprietary technology platform, aims to address cancer, diabetes, autoimmunity, and transplantation.
- The company is based in Vero Beach, Florida.
- The company's stock trades on the OTC market.
Competitors & Peers
Strengths
- Proprietary technology platform (MultiPharm).
- Targeted approach to cancer treatment with Pritumumab.
- Potential to expand into other therapeutic areas (diabetes, autoimmunity, transplantation).
- Experienced leadership team.
Weaknesses
- Clinical-stage company with no approved products.
- Reliance on successful development and commercialization of Pritumumab.
- Limited financial resources.
- Trading on the OTC market.
Catalysts
- Upcoming: Announcement of clinical trial results for Pritumumab.
- Upcoming: Potential strategic partnerships with larger pharmaceutical companies.
- Ongoing: Development of new therapies using the MultiPharm platform.
Risks
- Potential: Failure to obtain regulatory approval for Pritumumab.
- Ongoing: Competition from other biotechnology and pharmaceutical companies.
- Potential: Difficulty raising capital.
- Ongoing: Limited financial resources.
- Ongoing: Trading on the OTC market.
Growth Opportunities
- Advancement of Pritumumab: The successful completion of clinical trials for Pritumumab and subsequent regulatory approval represent a significant growth opportunity for Nascent Biotech. The market for brain cancer therapies is substantial, with a growing need for more effective treatments. Positive clinical data could lead to partnerships with larger pharmaceutical companies for commercialization, providing a significant revenue stream. The timeline for this growth opportunity depends on the progress of clinical trials and regulatory review processes.
- Expansion of MultiPharm Platform: The MultiPharm platform offers a broader growth opportunity by extending the company's focus beyond cancer to include diabetes, autoimmunity, and transplantation. These are large and growing markets with significant unmet needs. Successful development of therapies using the MultiPharm platform could diversify the company's revenue streams and reduce its reliance on Pritumumab. The timeline for this growth opportunity is longer-term, as it requires further research and development.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with other biotechnology or pharmaceutical companies can accelerate the development and commercialization of Nascent Biotech's therapies. Collaborations can provide access to additional funding, expertise, and resources. These partnerships can also expand the company's market reach and increase its visibility within the industry. The timing of these partnerships is uncertain but could occur at any stage of development.
- Expansion into New Geographic Markets: While the company is based in the US, expanding into new geographic markets, such as Europe or Asia, could increase its potential customer base and revenue. This expansion would require navigating different regulatory environments and establishing distribution networks. The timeline for this growth opportunity depends on the company's resources and strategic priorities.
- Acquisition or Merger: Nascent Biotech could be acquired by a larger pharmaceutical company seeking to expand its portfolio of cancer therapies. An acquisition would provide a significant return to investors. Alternatively, Nascent Biotech could merge with another biotechnology company to create a larger, more diversified entity. The timing of an acquisition or merger is uncertain and depends on market conditions and the company's performance.
Opportunities
- Positive clinical trial results for Pritumumab.
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into new geographic markets.
- Development of new therapies using the MultiPharm platform.
Threats
- Failure to obtain regulatory approval for Pritumumab.
- Competition from other biotechnology and pharmaceutical companies.
- Unfavorable changes in the regulatory environment.
- Difficulty raising capital.
Competitive Advantages
- Proprietary technology platform (MultiPharm).
- Patents protecting their monoclonal antibody therapies.
- Clinical data supporting the efficacy and safety of Pritumumab.
- Expertise in developing monoclonal antibody therapies.
About NBIO
Nascent Biotech, Inc., based in Vero Beach, Florida, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative monoclonal antibody therapies for various forms of cancer. The company's primary focus is on Pritumumab, a drug designed to treat patients suffering from brain cancer malignancies such as glioblastoma and malignant astrocytoma. Pritumumab also targets epithelial cancers, including lung, breast, colon, brain, and pancreas cancer, representing a broad therapeutic potential. In addition to Pritumumab, Nascent Biotech is developing MultiPharm, a proprietary technology platform aimed at cancer therapy, as well as addressing other significant health challenges like diabetes, autoimmunity, and transplantation. While the company's founding story and early evolution details are not available, its current strategy centers on advancing Pritumumab through clinical trials and further developing the MultiPharm platform. Nascent Biotech operates within the highly competitive biotechnology sector, striving to differentiate itself through its targeted approach to cancer treatment and its broader ambitions with the MultiPharm platform. The company's success hinges on the successful completion of clinical trials, regulatory approvals, and effective commercialization of its therapies.
What They Do
- Develop monoclonal antibody therapies for cancer treatment.
- Focus on Pritumumab, a drug targeting brain cancer malignancies and epithelial cancers.
- Develop the MultiPharm platform for cancer therapy, diabetes, autoimmunity, and transplantation.
- Conduct clinical trials to evaluate the safety and efficacy of their therapies.
- Seek regulatory approval from agencies like the FDA.
- Potentially partner with larger pharmaceutical companies for commercialization.
Business Model
- Develop and patent novel monoclonal antibody therapies.
- Conduct clinical trials to demonstrate efficacy and safety.
- Seek regulatory approval for commercialization.
- Out-license or partner with larger pharmaceutical companies for manufacturing and distribution.
Industry Context
Nascent Biotech operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The industry is driven by innovation and the constant pursuit of new treatments for diseases with unmet needs. Nascent Biotech's focus on monoclonal antibodies for cancer treatment aligns with a major trend in the industry, as these therapies have shown promise in targeting cancer cells with greater precision. Competitors like BSYI, CHNXF, CWWBF, FCHS, and PZOO also operate in the biotechnology space, developing various therapies and technologies.
Key Customers
- Patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma.
- Patients with epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
- Potentially, patients with diabetes, autoimmune diseases, and those requiring transplantation (through MultiPharm platform).
Financials
Chart & Info
Nascent Biotech, Inc. (NBIO) stock price: Price data unavailable
Latest News
No recent news available for NBIO.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NBIO.
Price Targets
Wall Street price target analysis for NBIO.
MoonshotScore
What does this score mean?
The MoonshotScore rates NBIO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Sean Carrick
CEO
Sean Carrick serves as the CEO of Nascent Biotech, Inc. Information regarding his prior experience and educational background is not available. As CEO, he is responsible for leading the company's strategic direction, overseeing its operations, and driving the development of its pipeline of monoclonal antibody therapies. He is also responsible for managing the company's financial resources and building relationships with investors and partners.
Track Record: Due to limited information, Sean Carrick's specific achievements and strategic decisions as CEO of Nascent Biotech, Inc. cannot be assessed. His tenure length is also unknown. Further information is needed to evaluate his performance and impact on the company's milestones.
NBIO OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Nascent Biotech may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Higher risk of price manipulation.
- Potential for delisting or suspension of trading.
- Lack of regulatory oversight.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Review the company's legal and regulatory compliance.
- Consult with a financial advisor before investing.
- Check for any news or press releases about the company.
- Development of monoclonal antibody therapies.
- Focus on cancer treatment.
- Proprietary technology platform (MultiPharm).
Common Questions About NBIO
What does Nascent Biotech, Inc. do?
Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing monoclonal antibody therapies for the treatment of various forms of cancer. Their lead drug candidate, Pritumumab, targets brain cancer malignancies and epithelial cancers. Additionally, they are developing the MultiPharm platform, which aims to address cancer, diabetes, autoimmunity, and transplantation. As a clinical-stage company, they are currently focused on advancing their drug candidates through clinical trials and seeking regulatory approvals.
What do analysts say about NBIO stock?
As of 2026-03-15, formal analyst ratings and price targets for Nascent Biotech (NBIO) are unavailable, likely due to its OTC market listing and small market capitalization. The company's valuation is influenced by the potential success of Pritumumab and the MultiPharm platform. Investors should conduct their own due diligence and consider the inherent risks associated with clinical-stage biotechnology companies and OTC-listed stocks.
What are the main risks for NBIO?
Nascent Biotech faces several key risks inherent to clinical-stage biotechnology companies. These include the risk of failure to obtain regulatory approval for Pritumumab, competition from other companies developing cancer therapies, the need for significant capital to fund research and development, and the risks associated with trading on the OTC market, such as low liquidity and limited financial disclosure. These factors contribute to the high-risk nature of investing in NBIO.
What are the key factors to evaluate for NBIO?
Nascent Biotech, Inc. (NBIO) currently holds an AI score of 42/100, indicating low score. Key strength: Proprietary technology platform (MultiPharm).. Primary risk to monitor: Potential: Failure to obtain regulatory approval for Pritumumab.. This is not financial advice.
How frequently does NBIO data refresh on this page?
NBIO prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven NBIO's recent stock price performance?
Recent price movement in Nascent Biotech, Inc. (NBIO) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary technology platform (MultiPharm).. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider NBIO overvalued or undervalued right now?
Determining whether Nascent Biotech, Inc. (NBIO) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying NBIO?
Before investing in Nascent Biotech, Inc. (NBIO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- OTC market listing increases investment risk.